Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 120 of 123 entries
Sorted by: Best Match Show Resources per page
A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy.

Asian journal of urology

Storås AH, Sanda MG, Garin O, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD.
PMID: 32257809
Asian J Urol. 2020 Apr;7(2):161-169. doi: 10.1016/j.ajur.2019.08.001. Epub 2019 Aug 19.

OBJECTIVE: To compare pre- and post-radical prostatectomy (RP) responses in the urinary incontinence domain of Expanded Prostate Cancer Index Composite-26 (EPIC-26) in cohorts from the USA, Norway and Spain.METHODS: A prospective study of pre- and 1-year post-treatment responses in...

Cite
Storås AH, Sanda MG, Garin O, et al. A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian J Urol. 2019;7(2):161-169doi: 10.1016/j.ajur.2019.08.001.
Storås, A. H., Sanda, M. G., Garin, O., Chang, P., Patil, D., Crociani, C., Suarez, J. F., Cvancarova, M., Loge, J. H., & Fosså, S. D. (2020). A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian journal of urology, 7(2), 161-169. https://doi.org/10.1016/j.ajur.2019.08.001
Storås, Anne Holck, et al. "A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy." Asian journal of urology vol. 7,2 (2020): 161-169. doi: https://doi.org/10.1016/j.ajur.2019.08.001
Storås AH, Sanda MG, Garin O, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD. A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian J Urol. 2020 Apr;7(2):161-169. doi: 10.1016/j.ajur.2019.08.001. Epub 2019 Aug 19. PMID: 32257809; PMCID: PMC7096671.
Copy Download .nbib Format: NLM
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.

Frontiers in medicine

Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø.
PMID: 32411717
Front Med (Lausanne). 2020 Apr 29;7:162. doi: 10.3389/fmed.2020.00162. eCollection 2020.

No abstract available.

Cite
Rekeland IG, Fosså A, Lande A, et al. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Front Med (Lausanne). 2020;7:162doi: 10.3389/fmed.2020.00162.
Rekeland, I. G., Fosså, A., Lande, A., Ktoridou-Valen, I., Sørland, K., Holsen, M., Tronstad, K. J., Risa, K., Alme, K., Viken, M. K., Lie, B. A., Dahl, O., Mella, O., & Fluge, �. �. (2020). Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine, 7162. https://doi.org/10.3389/fmed.2020.00162
Rekeland, Ingrid G, et al. "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study." Frontiers in medicine vol. 7 (2020): 162. doi: https://doi.org/10.3389/fmed.2020.00162
Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Front Med (Lausanne). 2020 Apr 29;7:162. doi: 10.3389/fmed.2020.00162. eCollection 2020. PMID: 32411717; PMCID: PMC7201056.
Copy Download .nbib Format: NLM
Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.

JNCI cancer spectrum

Agrawal V, Dinh PC, Fung C, Monahan PO, Althouse SK, Norton K, Cary C, Einhorn L, Fossa SD, Adra N, Travis LB.
PMID: 32190815
JNCI Cancer Spectr. 2019 Oct 08;4(2):pkz079. doi: 10.1093/jncics/pkz079. eCollection 2020 Apr.

We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk...

Cite
Agrawal V, Dinh PC, Fung C, et al. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI Cancer Spectr. 2019;4(2):pkz079doi: 10.1093/jncics/pkz079.
Agrawal, V., Dinh, P. C., Fung, C., Monahan, P. O., Althouse, S. K., Norton, K., Cary, C., Einhorn, L., Fossa, S. D., Adra, N., & Travis, L. B. (2020). Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI cancer spectrum, 4(2), pkz079. https://doi.org/10.1093/jncics/pkz079
Agrawal, Vaibhav, et al. "Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management." JNCI cancer spectrum vol. 4,2 (2020): pkz079. doi: https://doi.org/10.1093/jncics/pkz079
Agrawal V, Dinh PC, Fung C, Monahan PO, Althouse SK, Norton K, Cary C, Einhorn L, Fossa SD, Adra N, Travis LB. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI Cancer Spectr. 2019 Oct 08;4(2):pkz079. doi: 10.1093/jncics/pkz079. eCollection 2020 Apr. PMID: 32190815; PMCID: PMC7065712.
Copy Download .nbib Format: NLM
The CONSORT statement.

JAMA

Ross SD.
PMID: 8968010
JAMA. 1996 Dec 18;276(23):1877; author reply 1877. doi: 10.1001/jama.276.23.1877b.

No abstract available.

Cite
Ross SD. The CONSORT statement. JAMA. 1996;276(23):1877; author reply 1877doi: 10.1001/jama.276.23.1877b.
Ross, S. D. (1996). The CONSORT statement. JAMA, 276(23), 1877; author reply 1877. https://doi.org/10.1001/jama.276.23.1877b
Ross, S D. "The CONSORT statement." JAMA vol. 276,23 (1996): 1877; author reply 1877. doi: https://doi.org/10.1001/jama.276.23.1877b
Ross SD. The CONSORT statement. JAMA. 1996 Dec 18;276(23):1877; author reply 1877. doi: 10.1001/jama.276.23.1877b. PMID: 8968010.
Copy Download .nbib Format: NLM
Diagnostic Differences for Anterior Knee Pain between Sexes in Adolescent Basketball Players.

Journal of athletic enhancement

Foss KD, Myer GD, Magnussen RA, Hewett TE.
PMID: 25362859
J Athl Enhanc. 2014 Jan 10;3(1). doi: 10.4172/2324-9080.1000139.

BACKGROUND: The purpose of this study was to determine if there is a sex difference in the prevalence of specific patellofemoral disorders that cause anterior knee pain in adolescent basketball players undergoing pre-participation screening.METHODS: SETTING: Biomechanical Laboratory.METHODS: PARTICIPANTS: A...

Cite
Foss KD, Myer GD, Magnussen RA, et al. Diagnostic Differences for Anterior Knee Pain between Sexes in Adolescent Basketball Players. J Athl Enhanc. 2014;3(1)doi: 10.4172/2324-9080.1000139.
Foss, K. D., Myer, G. D., Magnussen, R. A., & Hewett, T. E. (2014). Diagnostic Differences for Anterior Knee Pain between Sexes in Adolescent Basketball Players. Journal of athletic enhancement, 3(1), . https://doi.org/10.4172/2324-9080.1000139
Foss, Kim D Barber, et al. "Diagnostic Differences for Anterior Knee Pain between Sexes in Adolescent Basketball Players." Journal of athletic enhancement vol. 3,1 (2014). doi: https://doi.org/10.4172/2324-9080.1000139
Foss KD, Myer GD, Magnussen RA, Hewett TE. Diagnostic Differences for Anterior Knee Pain between Sexes in Adolescent Basketball Players. J Athl Enhanc. 2014 Jan 10;3(1). doi: 10.4172/2324-9080.1000139. PMID: 25362859; PMCID: PMC4214064.
Copy Download .nbib Format: NLM
Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE).

JMIR research protocols

van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P, van Dulmen-den Broeder E.
PMID: 30215599
JMIR Res Protoc. 2018 Sep 14;7(9):e10824. doi: 10.2196/10824.

BACKGROUND: Despite a significant number of studies on female fertility following childhood, adolescent, and young adult (CAYA) cancer, studies establishing precise (dose-related) estimates of treatment-related risks are still scarce. Previous studies have been underpowered, did not include detailed treatment...

Cite
van den Berg M, van Dijk M, Byrne J, et al. Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Res Protoc. 2018;7(9):e10824doi: 10.2196/10824.
van den Berg, M., van Dijk, M., Byrne, J., Campbell, H., Berger, C., Borgmann-Staudt, A., Calaminus, G., Dirksen, U., Winther, J. F., Fossa, S. D., Grabow, D., Grandage, V. L., van den Heuvel-Eibrink, M. M., Kaiser, M., Kepak, T., Kremer, L. C., Kruseova, J., Kuehni, C. E., Lambalk, C. B., van Leeuwen, F. E., Leiper, A., Modan-Moses, D., Morsellino, V., Spix, C., Kaatsch, P., van Dulmen-den Broeder, E. (2018). Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR research protocols, 7(9), e10824. https://doi.org/10.2196/10824
van den Berg, Marleen, et al. "Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE)." JMIR research protocols vol. 7,9 (2018): e10824. doi: https://doi.org/10.2196/10824
van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P, van Dulmen-den Broeder E. Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Res Protoc. 2018 Sep 14;7(9):e10824. doi: 10.2196/10824. PMID: 30215599; PMCID: PMC6231763.
Copy Download .nbib Format: NLM
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

European urology

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.
PMID: 28705540
Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11.

BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.OBJECTIVE: To report...

Cite
Parker CC, Coleman RE, Sartor O, et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2017;73(3):427-435doi: 10.1016/j.eururo.2017.06.021.
Parker, C. C., Coleman, R. E., Sartor, O., Vogelzang, N. J., Bottomley, D., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Bruland, �. �. S., Petrenciuc, O., Staudacher, K., Li, R., & Nilsson, S. (2018). Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European urology, 73(3), 427-435. https://doi.org/10.1016/j.eururo.2017.06.021
Parker, Christopher C, et al. "Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial." European urology vol. 73,3 (2018): 427-435. doi: https://doi.org/10.1016/j.eururo.2017.06.021
Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11. PMID: 28705540.
Copy Download .nbib Format: NLM
How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting.

Cancer imaging : the official publication of the International Cancer Imaging Society

Colleran GC, Kwatra N, Oberg L, Grant FD, Drubach L, Callahan MJ, MacDougall RD, Fahey FH, Voss SD.
PMID: 29116015
Cancer Imaging. 2017 Nov 07;17(1):28. doi: 10.1186/s40644-017-0130-8.

PET/CT plays an important role in the diagnosis, staging and management of many pediatric malignancies. The techniques for performing PET/CT examinations in children have evolved, with increasing attention focused on reducing patient exposure to ionizing radiation dose whenever possible...

Cite
Colleran GC, Kwatra N, Oberg L, et al. How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer Imaging. 2017;17(1):28doi: 10.1186/s40644-017-0130-8.
Colleran, G. C., Kwatra, N., Oberg, L., Grant, F. D., Drubach, L., Callahan, M. J., MacDougall, R. D., Fahey, F. H., & Voss, S. D. (2017). How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer imaging : the official publication of the International Cancer Imaging Society, 17(1), 28. https://doi.org/10.1186/s40644-017-0130-8
Colleran, Gabrielle C, et al. "How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting." Cancer imaging : the official publication of the International Cancer Imaging Society vol. 17,1 (2017): 28. doi: https://doi.org/10.1186/s40644-017-0130-8
Colleran GC, Kwatra N, Oberg L, Grant FD, Drubach L, Callahan MJ, MacDougall RD, Fahey FH, Voss SD. How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer Imaging. 2017 Nov 07;17(1):28. doi: 10.1186/s40644-017-0130-8. PMID: 29116015; PMCID: PMC5678769.
Copy Download .nbib Format: NLM
A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study).

Cancers

Dahl AA, Kiserud CE, Fosså SD, Loge JH, Reinertsen KV, Ruud E, Lie HC.
PMID: 34830953
Cancers (Basel). 2021 Nov 18;13(22). doi: 10.3390/cancers13225800.

BACKGROUND: A major depressive episode (MDE) is typically self-rated by screening forms identifying probable MDE (pMDE). This population-based cross-sectional questionnaire study examined the prevalence rates of pMDE identified by the PHQ-9 screener in long-term survivors of childhood and adolescence...

Cite
Dahl AA, Kiserud CE, Fosså SD, et al. A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study). Cancers (Basel). 2021;13(22)doi: 10.3390/cancers13225800.
Dahl, A. A., Kiserud, C. E., Fosså, S. D., Loge, J. H., Reinertsen, K. V., Ruud, E., & Lie, H. C. (2021). A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study). Cancers, 13(22), . https://doi.org/10.3390/cancers13225800
Dahl, Alv A, et al. "A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study)." Cancers vol. 13,22 (2021). doi: https://doi.org/10.3390/cancers13225800
Dahl AA, Kiserud CE, Fosså SD, Loge JH, Reinertsen KV, Ruud E, Lie HC. A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study). Cancers (Basel). 2021 Nov 18;13(22). doi: 10.3390/cancers13225800. PMID: 34830953; PMCID: PMC8616399.
Copy Download .nbib Format: NLM
Electronic Spectroscopy of .

The journal of physical chemistry. A

Ross SD, Flores J, Hewett DM, Reilly NJ.
PMID: 34260230
J Phys Chem A. 2021 Jul 29;125(29):6420-6436. doi: 10.1021/acs.jpca.1c04496. Epub 2021 Jul 14.

The

Cite
Ross SD, Flores J, Hewett DM, et al. Electronic Spectroscopy of . J Phys Chem A. 2021;125(29):6420-6436doi: 10.1021/acs.jpca.1c04496.
Ross, S. D., Flores, J., Hewett, D. M., & Reilly, N. J. (2021). Electronic Spectroscopy of . The journal of physical chemistry. A, 125(29), 6420-6436. https://doi.org/10.1021/acs.jpca.1c04496
Ross, Sederra D, et al. "Electronic Spectroscopy of ." The journal of physical chemistry. A vol. 125,29 (2021): 6420-6436. doi: https://doi.org/10.1021/acs.jpca.1c04496
Ross SD, Flores J, Hewett DM, Reilly NJ. Electronic Spectroscopy of . J Phys Chem A. 2021 Jul 29;125(29):6420-6436. doi: 10.1021/acs.jpca.1c04496. Epub 2021 Jul 14. PMID: 34260230.
Copy Download .nbib Format: NLM
Needs for information about lifestyle and rehabilitation in long-term young adult cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Thorsen L, Bøhn SH, Lie HC, Fosså SD, Kiserud CE.
PMID: 34333716
Support Care Cancer. 2022 Jan;30(1):521-533. doi: 10.1007/s00520-021-06418-z. Epub 2021 Aug 01.

BACKGROUND: Healthy lifestyle and rehabilitation may mitigate late effects after cancer treatment, but knowledge about lifestyle and rehabilitation information needs among long-term young adult cancer survivors (YACSs) (≥ 5 years from diagnosis) is limited. The present study aimed to...

Cite
Thorsen L, Bøhn SH, Lie HC, et al. Needs for information about lifestyle and rehabilitation in long-term young adult cancer survivors. Support Care Cancer. 2021;30(1):521-533doi: 10.1007/s00520-021-06418-z.
Thorsen, L., Bøhn, S. H., Lie, H. C., Fosså, S. D., & Kiserud, C. E. (2022). Needs for information about lifestyle and rehabilitation in long-term young adult cancer survivors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30(1), 521-533. https://doi.org/10.1007/s00520-021-06418-z
Thorsen, Lene, et al. "Needs for information about lifestyle and rehabilitation in long-term young adult cancer survivors." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 30,1 (2022): 521-533. doi: https://doi.org/10.1007/s00520-021-06418-z
Thorsen L, Bøhn SH, Lie HC, Fosså SD, Kiserud CE. Needs for information about lifestyle and rehabilitation in long-term young adult cancer survivors. Support Care Cancer. 2022 Jan;30(1):521-533. doi: 10.1007/s00520-021-06418-z. Epub 2021 Aug 01. PMID: 34333716; PMCID: PMC8636439.
Copy Download .nbib Format: NLM
A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome.

JCI insight

Hoel F, Hoel A, Pettersen IK, Rekeland IG, Risa K, Alme K, Sørland K, Fosså A, Lien K, Herder I, Thürmer HL, Gotaas ME, Schäfer C, Berge RK, Sommerfelt K, Marti HP, Dahl O, Mella O, Fluge Ø, Tronstad KJ.
PMID: 34423789
JCI Insight. 2021 Aug 23;6(16). doi: 10.1172/jci.insight.149217.

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease usually presenting after infection. Emerging evidence supports that energy metabolism is affected in ME/CFS, but a unifying metabolic phenotype has not been firmly established. We performed global metabolomics, lipidomics, and...

Cite
Hoel F, Hoel A, Pettersen IK, et al. A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. 2021;6(16)doi: 10.1172/jci.insight.149217.
Hoel, F., Hoel, A., Pettersen, I. K., Rekeland, I. G., Risa, K., Alme, K., Sørland, K., Fosså, A., Lien, K., Herder, I., Thürmer, H. L., Gotaas, M. E., Schäfer, C., Berge, R. K., Sommerfelt, K., Marti, H. P., Dahl, O., Mella, O., Fluge, �. �., & Tronstad, K. J. (2021). A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI insight, 6(16), . https://doi.org/10.1172/jci.insight.149217
Hoel, Fredrik, et al. "A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome." JCI insight vol. 6,16 (2021). doi: https://doi.org/10.1172/jci.insight.149217
Hoel F, Hoel A, Pettersen IK, Rekeland IG, Risa K, Alme K, Sørland K, Fosså A, Lien K, Herder I, Thürmer HL, Gotaas ME, Schäfer C, Berge RK, Sommerfelt K, Marti HP, Dahl O, Mella O, Fluge Ø, Tronstad KJ. A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. 2021 Aug 23;6(16). doi: 10.1172/jci.insight.149217. PMID: 34423789; PMCID: PMC8409979.
Copy Download .nbib Format: NLM
Showing 109 to 120 of 123 entries